(Q46025973)

18 December 2017

title

Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. (English)

1 reference

18 December 2017

1 reference

angiogenesis inhibitor

1 reference

1 reference

6

1 reference

18 December 2017

author name string

Bee K Tan

1

1 reference

18 December 2017

Raghu Adya

2

1 reference

18 December 2017

Jing Chen

3

1 reference

18 December 2017

Syed Farhatullah

4

1 reference

18 December 2017

Dennis Heutling

5

1 reference

18 December 2017

Hendrik Lehnert

7

1 reference

18 December 2017

Harpal S Randeva

8

1 reference

18 December 2017

publication date

4 May 2009

1 reference

18 December 2017

published in

Cardiovascular Research

1 reference

18 December 2017

volume

83

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

566-574

1 reference

18 December 2017

Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Immunohistochemical localisation of thrombospondin in human megakaryocytes and platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Thrombospondin-based antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Thrombospondin-1 is a major activator of TGF-beta1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Angiogenesis and inflammation in carotid atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP131

21 January 2018

Identifiers

DOI

10.1093/CVR/CVP131

1 reference

18 December 2017

1 reference

18 December 2017